THE USE OF SPECIFIED TCF TARGET GENES TO IDENTIFY DRUGS FOR THE TREATMENT OF CANCER, IN PARTICULAR COLORECTAL CANCER, IN WHICH TCF/ Beta-CATENIN/WNT SIGNALLING PLAYS A CENTRAL ROLE

Details for Australian Patent Application No. 2003253046 (hide)

Event Publications

30 October 2003 Complete Application Filed

Priority application(s): 02077711.6 08.07.02 EP; 10/197,619 16.07.02 US

11 March 2004 Application Open to Public Inspection

Published as AU-A-2003253046

31 May 2007 Assignment before Grant

Kylix B.V. The application has been assigned to Kiadis Pharma B.V. Assignments before Grant, Section 113

5 February 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.